ライフサイエンスコーパス: Ebola virus

1 viruses, such as measles, rabies virus, and Ebola virus.

2 primer site binding mismatches in the Ituri Ebola virus.

3 n, medical countermeasures, and evolution of Ebola virus.

4 gnostic tests with the outbreak strain Ituri Ebola virus.

5 an primary dendritic cells and the unrelated Ebola virus.

6 d to have survived congenital infection with Ebola virus.

7 ety of negative-sense RNA viruses, including Ebola virus.

8 o develop a therapeutic mAb cocktail against Ebola virus.

9 en immune responses against known pathogenic Ebola viruses.

10 y extend protective immune responses against Ebola viruses.

11 ronic detection of IgG antibodies to HIV and Ebola viruses.

12 NHPs are most likely intermediate hosts for Ebola viruses.

13 pidemics such as those caused by the HIV and Ebola viruses.

14 Funding for Ebola virus ($1.2 billion), Zika virus ($0.3 billion), i

15 s including crucial mutations in VP24 enable Ebola virus adaptation to new hosts.

16 >=37.5oC necessitating urgent screening for Ebola virus and a small number developed persistent arth

17 E Marburg virus (MARV) is a virus similar to Ebola virus and also causes a hemorrhagic disease which

18 Investments for high-threat pathogens (eg, Ebola virus and coronavirus) were often reactive and fol

19 enes (ISGs) against a biologically contained Ebola virus and identify several ISGs not previously kno

20 Entry inhibition was relatively robust for Ebola virus and influenza virus, modest for VSV, and mil

21 texposure treatments against the filoviruses Ebola virus and Marburg virus (MARV); however, the mecha

22 iruses, and previous studies with RdRps from Ebola virus and Middle East respiratory syndrome coronav

23 haemorrhagic fevers such as those caused by Ebola virus and other filoviruses.

24 Lessons learned from the recent Ebola virus and Zika virus epidemics are that delay in d

25 t neutralized all four pathogenic species of Ebola viruses and elicited antibody-dependent cell-media

26 cellular immune responses against pathogenic Ebola viruses and support further evaluation of this app

27 egrees C, necessitating urgent screening for Ebola virus, and a small number developed persistent art

28 o define positivity, we showed that specific Ebola virus antibodies are not widespread among NHPs.

29 emerging viral pathogens, including HIV and Ebola viruses, are most prevalent in regions of the worl

30 (with a selectivity index of 303) and Makona Ebola virus at 13nM (with a selectivity index of 279).

31 Remdesivir inhibited Ituri Ebola virus at a 50% effective concentration (EC(50)) of

32 sease, neutralizes both Bundibugyo virus and Ebola virus, but not Sudan virus.

33 Bats are considered a reservoir species for Ebola viruses, but nonhuman primates (NHPs) have represe

34 roles in infection prevention and control of Ebola virus by decontaminating high-touch environmental

35 a venous blood specimen tested negative for Ebola virus by quantitative reverse-transcription polyme

36 Ebola virus causes devastating hemorrhagic fever outbrea

37 Filoviruses such as Ebola virus continue to pose a substantial health risk t

38 ibit both LASV and EBOV.IMPORTANCE Lassa and Ebola viruses continue to cause severe outbreaks in huma

39 ing antivirals.IMPORTANCE The development of Ebola virus countermeasures is challenged by our limited

40 mory B cells from four survivors treated for Ebola virus disease (EVD) 1 or 3 months after discharge

41 ach of these factors, to predict the risk of Ebola virus disease (EVD) across time and space.

42 f viral hemorrhagic fevers (VHFs), including Ebola virus disease (EVD) and Lassa fever (LF), highligh

43 5, a 15-year-old boy received a diagnosis of Ebola virus disease (EVD) at the John F.

44 ne the occurrence of previously undocumented Ebola virus disease (EVD) cases and infections, and to r

45 aper, we developed a compartmental model for Ebola virus disease (EVD) dynamics, which includes three

46 During the Ebola virus disease (EVD) epidemic in Western Africa (20

47 though several experimental therapeutics for Ebola virus disease (EVD) have been developed, the safet

48 Clinical sequelae of Ebola virus disease (EVD) have not been described more t

49 treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients.

50 ne candidates.IMPORTANCE The pathogenesis of Ebola virus disease (EVD) in humans is complex, and the

51 isual impairment in a cohort of survivors of Ebola virus disease (EVD) in Monrovia, Liberia.

52 rrently being used to combat the outbreak of Ebola virus disease (EVD) in the Democratic Republic of

53 orker presenting with a late reactivation of Ebola virus disease (EVD) in the UK.

54 orker presenting with a late reactivation of Ebola virus disease (EVD) in the United Kingdom.

55 The recent large outbreak of Ebola virus disease (EVD) in Western Africa resulted in

56 Ebola virus disease (EVD) is a severe and frequently let

57 The 2018 Ebola virus disease (EVD) outbreak in Equateur Province,

58 genomic information at the start of the 2018 Ebola virus disease (EVD) outbreak in North Kivu Provinc

59 The Ebola virus disease (EVD) outbreak in West Africa betwee

60 ublic of the Congo (DRC) recorded its eighth Ebola virus disease (EVD) outbreak, approximately 3 year

61 ing the late phase of the large West-African Ebola virus disease (EVD) outbreak, the majority of pati

62 In this study, serum antibodies from Ebola virus disease (EVD) survivors from Sierra Leone we

63 ic, auditory, and visual complications among Ebola virus disease (EVD) survivors.

64 ic, auditory, and visual complications among Ebola Virus Disease (EVD) survivors; however, little is

65 nical trials and used to treat patients with Ebola virus disease (EVD) toward the end of the epidemic

66 Recent and ongoing outbreaks of Ebola virus disease (EVD) underscore the unpredictable n

67 infectious it could explain re-emergences of Ebola virus disease (EVD) without known contact.

68 For highly contagious diseases such as Ebola virus disease (EVD), interpersonal contact plays t

69 evidence of subclinical and paucisymptomatic Ebola Virus Disease (EVD), the prevalence and associated

70 Zaire ebolavirus (EBOV) causes Ebola virus disease (EVD), which carries a fatality rate

71 ajor contributor to outcome in patients with Ebola virus disease (EVD), with high values leading to a

72 is a frequently recommended intervention in Ebola virus disease (EVD), yet its impact on patient out

73 preventive behaviours during an outbreak of Ebola virus disease (EVD).

74 Abs) is a promising therapeutic approach for Ebola virus disease (EVD).

75 dies are key components to prevent and treat Ebola virus disease (EVD).

76 problems have been reported in survivors of Ebola virus disease (EVD).

77 trol of virus replication, viremia and fatal Ebola virus disease (EVD).

78 eptide, that is produced in abundance during Ebola virus disease (EVD).

79 ay persist in the semen of male survivors of Ebola Virus Disease (EVD).

80 ed, single-stranded RNA virus that can cause Ebola virus disease (EVD).

81 ortality did not differ between survivors of Ebola virus disease and the general population.

82 tality was high in people who recovered from Ebola virus disease and were discharged from Ebola treat

83 ene product could help prevent the spread of Ebola virus disease during outbreaks.

84 Inadequate access to rapid testing for Ebola virus disease during the 2014-to-2016 outbreak led

85 Following the Ebola virus disease epidemic in west Africa, there has b

86 onditions (based on the 2013-16 west African Ebola virus disease epidemic).

87 the general Guinean population, survivors of Ebola virus disease had a more than five-times increased

88 The 2014 West African outbreak of Ebola virus disease highlighted the urgent need to devel

89 symptoms observed in acute and convalescent Ebola virus disease in human patients.

90 The massive outbreak of Ebola virus disease in west Africa between 2013 and 2016

91 The Ebola virus disease outbreak in west Africa has prompted

92 Compared with pre-Ebola virus disease outbreak trends, significant decreas

93 nt targeting EBOV.IMPORTANCE The most recent Ebola virus disease outbreak, from 2014 to 2016, resulte

94 cs has been historically used to investigate Ebola virus disease outbreaks and how new technologies a

95 d safely implemented at scale in response to Ebola virus disease outbreaks in rural settings.

96 sts a critical role for the delta peptide in Ebola virus disease pathology and as a possible target f

97 l failure in late deaths after recovery from Ebola virus disease should be investigated.

98 ralize virus, despite never having developed Ebola virus disease symptoms, highlighting an important

99 The most commonly reported symptom of post-Ebola virus disease syndrome in survivors is arthralgia,

100 In March, 2016, a flare-up of Ebola virus disease was reported in Guinea, and in respo

101 ugh August 2016, 256343 specimens tested for Ebola virus disease were captured in the database.

102 done to gain information about survivors of Ebola virus disease who subsequently died from their clo

103 ed to contact and follow-up all survivors of Ebola virus disease who were discharged from Ebola treat

104 Of the 1270 survivors of Ebola virus disease who were discharged from Ebola treat

105 -ZEBOV offers substantial protection against Ebola virus disease, with no cases among vaccinated indi

106 ls, could play a role in vaccination against Ebola virus disease.

107 ltaG-ZEBOV-GP vaccine in persons at risk for Ebola virus disease.

108 protected non-human primates (NHPs) against Ebola virus disease.

109 the first licensed vaccine for prevention of Ebola virus disease.

110 ymptoms are the most common complications of Ebola virus disease.

111 tal organs contributes to the development of Ebola virus disease.IMPORTANCE Ebola virus (EBOV) remain

112 on of approved drugs to treat both Lassa and Ebola virus diseases.

113 More than 28 000 people were infected with Ebola virus during the 2014-2015 West African outbreak,

114 erested in identifying drugs that block both Ebola virus (EBOV) and Lassa virus (LASV), two unrelated

115 as13a-based (SHERLOCK) diagnostics targeting Ebola virus (EBOV) and Lassa virus (LASV), with both flu

116 e family Filoviridae Because the filoviruses Ebola virus (EBOV) and Marburg virus (MARV) modulate hos

117 generation sequencing (mNGS) to detect Zaire Ebola virus (EBOV) and other potential pathogens from wh

118 Recent outbreaks of Ebola virus (EBOV) and severe acute respiratory syndrome

119 incorporates glycoproteins (GPs) from Zaire Ebola virus (EBOV) and Sudan Ebola virus (SUDV) and is d

120 say platform for ultrasensitive detection of Ebola virus (EBOV) antigens.

121 rburg virus (MARV) is a filovirus related to Ebola virus (EBOV) associated with human hemorrhagic dis

122 Marburg virus (MARV) and Ebola virus (EBOV) belong to the family Filoviridae.

123 Ebola virus (EBOV) causes epidemics with high mortality

124 (NDV) have been previously evaluated against Ebola virus (EBOV) challenge.

125 Ebola virus (EBOV) continues to pose a significant threa

126 Ebola virus (EBOV) continues to pose significant threats

127 In response to the Ebola virus (EBOV) crisis of 2013-2016, a recombinant ve

128 The 2013-2016 Ebola virus (EBOV) disease epidemic demonstrated the gra

129 ed from 12 rhesus macaques that succumbed to Ebola virus (EBOV) disease from 5 to 8 days post exposur

130 Ebola virus (EBOV) disease has killed thousands of West

131 Ebola virus (EBOV) disease outbreaks, as well as the abi

132 evere and fatal illness epidemics such as of Ebola virus (EBOV) disease.

133 rkers (HCW) are more likely to be exposed to Ebola virus (EBOV) during an outbreak compared to people

134 ivatives of artemisinin, the beneficial anti-Ebola virus (EBOV) effect observed could possibly be att

135 Ebola virus (EBOV) entry into cells is mediated by its s

136 The Ebola virus (EBOV) envelope glycoprotein (GP) is a membr

137 Since the most recent outbreak, the Ebola virus (EBOV) epidemic remains one of the world's p

138 Ebola virus (EBOV) epidemics pose a major public health

139 The Ebola virus (EBOV) genome encodes a partly conserved 40-

140 ular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was su

141 Since its discovery in 1976, Ebola virus (EBOV) has caused numerous outbreaks of fata

142 g vaccine efficacy against the highly lethal Ebola virus (EBOV) in humans is almost impossible due to

143 Ebola virus (EBOV) inclusion bodies (IBs) are cytoplasmi

144 arameters responsible for survival following Ebola virus (EBOV) infection is paramount for developing

145 al antibodies can mediate protection against Ebola virus (EBOV) infection through direct neutralizati

146 rposes-proved disappointing in tests against Ebola virus (EBOV) infection, more recently, specific mo

147 we perform a screen for genes essential for Ebola virus (EBOV) infection.

148 Given that the Ebola virus (EBOV) infects a wide array of organs and ce

149 tion of EBOV VP40-mediated egress.IMPORTANCE Ebola virus (EBOV) is a high-priority, emerging human pa

150 Ebola virus (EBOV) is a highly lethal member of the Filo

151 Ebola virus (EBOV) is an enveloped, single-stranded RNA

152 g risk factors for household transmission of Ebola virus (EBOV) is important to guide preventive meas

153 Evidence from the 2013-2016 Ebola virus (EBOV) outbreak indicated that different gen

154 contribute to viral pathogenicity.IMPORTANCE Ebola virus (EBOV) outbreaks can claim numerous lives an

155 s have played a major role in propagation of Ebola virus (EBOV) outbreaks.

156 Evolution of antibody repertoire against the Ebola virus (EBOV) proteome was characterized in an acut

157 evelopment of Ebola virus disease.IMPORTANCE Ebola virus (EBOV) remains a high-priority pathogen sinc

158 Ebola virus (EBOV) remains a public health threat.

159 A key step in the Ebola virus (EBOV) replication cycle involves conformati

160 Persistence of Ebola virus (EBOV) RNA in semen samples from survivors w

161 s of targeted versus nontargeted violence on Ebola virus (EBOV) transmission in Democratic Republic o

162 The Ebola virus (EBOV) VP40 matrix protein (eVP40) orchestra

163 Ebola virus (EBOV), a member of the Filoviridae family,

164 for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against other ebolav

165 for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against outbreak-cau

166 ee classes of fusion proteins including HIV, Ebola virus (EBOV), influenza A virus (IAV) and Epstein

167 pathogens spread by close contact, including Ebola virus (EBOV), severe acute respiratory syndrome co

168 Ebola virus (EBOV), species Zaire ebolavirus, may persis

169 Several Ebola virus (EBOV)-specific and, more recently, pan-ebol

170 o vaccine or approved therapy against lethal Ebola virus (EBOV).

171 uman respiratory syncytial virus (HRSV), and Ebola virus (EBOV).

172 ported possible miRNA candidates produced by Ebola virus (EBOV).

173 vere and frequently lethal disease caused by Ebola virus (EBOV).

174 markably potent small molecule inhibitors of Ebola virus entry.

175 recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVDeltaG-ZE

176 or the deployment of the rVSVDeltaG-ZEBOV-GP Ebola virus envelope glycoprotein vaccine, available the

177 acute respiratory syndrome and west African Ebola virus epidemic, revealed serious shortcomings whic

178 The HAVCR1-NPC1 pathway, which Ebola virus exploits to infect cells(9), mediates HAV in

179 ensing strategy by using clinical samples of Ebola virus from patients.

180 e genetics system, we generated an authentic Ebola virus from the ongoing outbreak in Ituri and North

181 ogenetic analysis of representative complete Ebola virus genome sequences from previous outbreaks.

182 nt sequencing to produce two coding-complete Ebola virus genomes 5 days after declaration of the EVD

183 used target-enrichment sequencing to produce Ebola virus genomes from samples obtained in the 2018 Eq

184 2019;116:8535-8543) reported that Ebola virus genomes have variable 3' terminal nucleotide

185 sent words of the human genome were found in Ebola virus genomes.

186 Rapid Ebola virus genomic characterisation should be included

187 ructure of ADI-15946 in complex with cleaved Ebola virus glycoprotein (EBOV GP(CL)) reveals that bind

188 We designed novel synthetic anti-Ebola virus glycoprotein (EBOV-GP) DNA vaccines as a str

189 Recent studies demonstrate that the Ebola virus glycoprotein (GP) acquired an A82V change du

190 gulation of CD16, in response to recombinant Ebola virus glycoprotein and post-vaccine dose 1 and dos

191 High levels of binding and neutralizing anti-Ebola virus glycoprotein antibodies were induced by all

192 f normal immunocompetent mice.IMPORTANCE The Ebola virus glycoprotein contains a mucin-like domain wh

193 Studies using an Ebola virus glycoprotein fused to the Ag 85B epitope sho

194 For antibody testing, we used an Ebola virus glycoprotein IgG capture enzyme immunoassay

195 onstrated binding antibody responses against Ebola virus glycoprotein, and 87%-100% demonstrated neut

196 We found that wild-type Ebola virus glycoprotein, in the context of this platfor

197 that targets the receptor-binding domain of Ebola virus glycoprotein, which prevents mortality in rh

198 ely inhibit DC-SIGN-mediated augmentation of Ebola virus glycoprotein-driven cell entry (with IC(50)

199 ell tolerated and highly immunogenic against Ebola virus glycoprotein.

200 The BC-PIV vector harboring the Ebola virus GP gene was able to elicit neutralizing anti

201 Ebola virus GP vaccine with Matrix-M adjuvant is well to

202 The outbreak of the Ebola virus has resulted in significant morbidity and mo

203 A key viral factor in Ebola virus IB formation is the nucleoprotein, NP, which

204 of survivors in this population (eight anti-Ebola virus IgG seropositive) and report a case fatality

205 eaths and eight previously unrecognised anti-Ebola virus IgG-positive survivors, including one who ha

206 ty to inhibit the growth of infectious Ituri Ebola virus in cell culture.

207 To relate this virus to other Ebola viruses in DR Congo, we did a phylogenetic analysi

208 s or serological testing was used to confirm Ebola virus infection in suspected cases.

209 A record number of people survived Ebola virus infection in the 2013-16 outbreak in west Af

210 btain a diverse experimental data set of the Ebola virus infection in vitro, and then make use of Bay

211 ement of the joints in acute or convalescent Ebola virus infection is not well characterized in human

212 ment was accelerated in response to the 2014 Ebola virus infection outbreak.

213 Our findings provide insights into Ebola virus infection that could be exploited for the de

214 Ebola virus infection was more widespread in this spillo

215 In human Ebola virus infection, clinical outcome is strongly asso

216 several ISGs not previously known to affect Ebola virus infection.

217 There are no approved therapies for Ebola virus infection.

218 emographic variables and exposure level with Ebola virus infection.

219 utic agents for the treatment and control of Ebola virus infections.

220 ca experienced an unanticipated explosion of Ebola virus infections.

221 with entry mediated by the glycoproteins of Ebola virus, influenza virus, vesicular stomatitis virus

222 tion with Ad26.ZEBOV and MVA-BN-Filo against Ebola virus is well tolerated and immunogenic in healthy

223 degree of sequence conservation among GP of Ebola viruses, it would be challenging to determine the

224 A time course of infection study with Ebola virus/Kikwit found that the large joint synovium b

225 le (knee) is a target for acute infection by Ebola virus/Kikwit, Ebola virus/Makona-C05, and Marburg

226 ort the development of a bivalent, spherical Ebola virus-like particle (VLP) vaccine that incorporate

227 Symptoms were based on Ebola virus Makona variant EVD case definitions (focusin

228 tol Antiseptic Liquid (DAL) for inactivating Ebola virus (Makona C07 variant) (EBOV/Mak) within an or

229 ferent microbicidal actives for inactivating Ebola virus-Makona strain (EBOV/Mak) on stainless-steel

230 t for acute infection by Ebola virus/Kikwit, Ebola virus/Makona-C05, and Marburg virus/Angola in the

231 he past 50 years, several viruses, including Ebola virus, Marburg virus, Nipah virus, Hendra virus, s

232 ically closest, with 98.73% homology, to the Ebola virus Mayinga variant isolated from the first DRC

233 Ebola virus modelling efforts have primarily focused on

234 nt from the Zaireebolavirus species, denoted Ebola virus Muyembe, was obtained using next-generation

235 primed or prime-boosted with Marburg virus, Ebola virus, or Sosuga virus for the presence of virus-s

236 the control and clearance of Marburg virus, Ebola virus, or Sosuga virus infection in ERBs.

237 The ongoing Ebola virus outbreak in the Ituri and North Kivu Provinc

238 analysis of whole-genome sequences from each Ebola virus outbreak suggests there are at least two Ebo

239 cumenting the beginnings of the west African Ebola virus outbreak, reveal important insight into tran

240 effective and practical therapies for future Ebola virus outbreaks.

241 han close contacts more than 2 decades after Ebola virus outbreaks.

242 ld provide a rapid-response treatment during Ebola virus outbreaks.

243 rodrug that has been clinically evaluated in Ebola virus patients and recently received emergency use

244 g variants in ongoing outbreaks, and also in Ebola virus patients undergoing remdesivir therapy.

245 ingle amino acid substitution, F548S, in the Ebola virus polymerase conferred low-level reduced susce

246 Homology modeling suggests that the Ebola virus polymerase F548 residue lies in the F-motif

247 IFNs and, during the most recent outbreak of Ebola virus, questions regarding the suitability of the

248 The rabies and Ebola viruses recruit the highly conserved host protein

249 ity and mortality in the affected areas, and Ebola virus RNA has been found in the semen of the survi

250 We report the presence of Ebola virus RNA in semen in a cohort of survivors of EVD

251 This study modeled the presence of Ebola virus RNA in the semen of male Ebola survivors par

252 nts of any age who had a positive result for Ebola virus RNA on reverse-transcriptase-polymerase-chai

253 Recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) is the most advanced Ebola viru

254 recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) vaccine as an unlicensed emerge

255 Here, we wished to determine whether an anti-Ebola virus sdAb, that was cross-reactive within the Ebo

256 diagnostic assays for detection of the Ituri Ebola virus sequence.

257 Using Ebola virus sequences provided by organisations in DR Co

258 diagnostic assays detected Ituri and Makona Ebola virus sequences with similar sensitivities and eff

259 d assay for immunoglobulin G antibodies to 4 Ebola virus species.

260 The cycle threshold (Ct) of an Ebola virus-specific reverse transcription-polymerase ch

261 sion dynamics and risk factors that underpin Ebola virus spillover events.

262 rus outbreak suggests there are at least two Ebola virus strains in DR Congo, which have independentl

263 thal disease and lack targeted therapeutics: Ebola virus, Sudan virus and Bundibugyo virus.

264 GPs) from Zaire Ebola virus (EBOV) and Sudan Ebola virus (SUDV) and is designed to extend the breadth

265 Based on the mutations identified in the Ebola virus surface glycoprotein (GP(12)) observed in al

266 Understanding how the Ebola virus surface glycoprotein functions to facilitate

267 We identified nine amino acid changes in the Ebola virus surface glycoprotein, of which one resulted

268 We evaluated the potential for Ebola virus surrogates to be aerosolized from three type

269 Previous serologic studies suggest that some Ebola virus survivors exhibit delayed antibody responses

270 e utility of FDA-ARGOS reference genomes for Ebola virus target sequence comparison as part of a comp

271 purposes by detecting RNA from influenza and Ebola viruses, thus highlighting its suitability for int

272 imal reservoir and understand the ecology of Ebola viruses to inform disease control.

273 and HBV, while all isoforms equally inhibit Ebola virus transcription and replication.

274 profile of remdesivir by serially passaging Ebola virus under remdesivir selection; we generated lin

275 o, rapid identification of the species Zaire Ebola virus using partial gene amplification and nanopor

276 recombinant vesicular stomatitis virus-Zaire Ebola virus vaccine (rVSV-ZEBOV) as an unlicensed emerge

277 bola virus (rVSV-ZEBOV) is the most advanced Ebola virus vaccine candidate and is currently being use

278 ains an important need for prophylactic anti-Ebola virus vaccine candidates that elicit long-lasting

279 idered in rational design strategies for new Ebola virus vaccine candidates.IMPORTANCE The pathogenes

280 recombinant vesicular stomatitis virus-Zaire Ebola virus vaccine in the recommended ring vaccination

281 issemination of the causative agent, a novel Ebola virus variant closely related to the initial Mayin

282 using genomics to rapidly characterise a new Ebola virus variant within the timeframe of an outbreak.

283 evealed a distinct cluster, confirming a new Ebola virus variant, for which we propose the name "Tumb

284 hould be efficacious against the circulating Ebola virus variant.

285 to have evolved at a slower rate than other Ebola virus variants (0.69 x 10(-3) substitutions per si

286 ed by the Makona variant compared with other Ebola virus variants was lacking.

287 ence in other analogous proteins such as the Ebola virus VP35 evinces a broader purpose for LC8 in re

288 istinct oligomeric states of the Marburg and Ebola virus VP35 proteins may explain differences betwee

289 Although Ebola virus VP40 and GP both activate NF-kappaB independ

290 late from this outbreak, a recombinant Ituri Ebola virus was compared with a similarly engineered Mak

291 Testing for Ebola virus was done by real-time PCR and for malaria by

292 Ituri Ebola virus was similar to Makona in its susceptibility

293 This Ebola virus was the Zaire strain of the virus family Fil

294 Primer and probe mismatches to Ebola virus were identified in silico for all deployed d

295 piratory syndrome-associated coronavirus and Ebola virus, where HCP became infected while caring for

296 ptions of many viral infections, but for the Ebola virus, which requires biosafety level 4 facilities

297 nal antibodies 2G4 and 4G7 neutralised Ituri Ebola virus with a mean EC(50) of 0.24 mug/mL and 0.48 m

298 ) of 0.24 mug/mL and 0.48 mug/mL, and Makona Ebola virus with a mean EC(50) of 0.45 mug/mL and 0.2 mu

299 lder, and hip are a target for mouse-adapted Ebola virus/Yambuku-Mayinga infection during acute disea

300 Before vaccination, Zaire Ebola virus (ZEBOV)-glycoprotein (GP)-specific and ZEBOV